- Home
- JBDI vs SCYX Comparison
JBDI vs SCYX Comparison
Compare JBDI & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBDI
- SCYX
- Stock Information
- Founded
- JBDI 1983
- SCYX 1999
- Country
- JBDI Singapore
- SCYX United States
- Employees
- JBDI N/A
- SCYX N/A
- Industry
- JBDI
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- JBDI
- SCYX Health Care
- Exchange
- JBDI Nasdaq
- SCYX Nasdaq
- Market Cap
- JBDI 28.7M
- SCYX 32.3M
- IPO Year
- JBDI 2024
- SCYX 2014
- Fundamental
- Price
- JBDI $1.75
- SCYX $0.75
- Analyst Decision
- JBDI
- SCYX
- Analyst Count
- JBDI 0
- SCYX 0
- Target Price
- JBDI N/A
- SCYX N/A
- AVG Volume (30 Days)
- JBDI 310.9K
- SCYX 665.7K
- Earning Date
- JBDI 01-01-0001
- SCYX 11-05-2025
- Dividend Yield
- JBDI N/A
- SCYX N/A
- EPS Growth
- JBDI N/A
- SCYX N/A
- EPS
- JBDI N/A
- SCYX N/A
- Revenue
- JBDI $8,445,000.00
- SCYX $3,257,000.00
- Revenue This Year
- JBDI N/A
- SCYX $20.23
- Revenue Next Year
- JBDI N/A
- SCYX $933.90
- P/E Ratio
- JBDI N/A
- SCYX N/A
- Revenue Growth
- JBDI N/A
- SCYX N/A
- 52 Week Low
- JBDI $0.49
- SCYX $0.66
- 52 Week High
- JBDI $3.00
- SCYX $1.62
- Technical
- Relative Strength Index (RSI)
- JBDI 50.06
- SCYX 37.17
- Support Level
- JBDI $1.60
- SCYX $0.73
- Resistance Level
- JBDI $1.89
- SCYX $0.91
- Average True Range (ATR)
- JBDI 0.22
- SCYX 0.07
- MACD
- JBDI -0.04
- SCYX -0.01
- Stochastic Oscillator
- JBDI 24.00
- SCYX 13.77
About JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.